Abstract
BackgroundDirect targeting of KRAS is challenging and represents an unmet need. We identified SLC25A22, a mitochondrial glutamate transporter, as a potential therapeutic target in KRAS mutant colorectal cancer (CRC). In...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
